In accordance with previous results (8), patients with cancer in our study exhibited low frequencies of IgG+ B cells, with an average of 5.56% (SD = 2.26) from total CD19+ cells (Supplemental Figure 3), resulting in a low number of MET-binding B cells. This evidence concerns the gene CD19 and cancer.